A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.

被引：0
|
作者：
McWhirter, Elaine
Hamid, Omid
Chmielowski, Bartosz
Carvajal, Richard D.
Jaffray, David A.
Driscoll, Brandon
Shek, Tina
Yeung, Ivan
Keller, Harald
McKee, Trevor D.
Pearce, Tillman E.
Kroll, Stew
Joshua, Anthony M.
机构：
[1] Juravinski Canc Ctr, Hamilton, ON, Canada
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Threshold Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9089
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug
    Weiss, G. J.
    Infante, J. R.
    Borad, M.
    Langmuir, V. K.
    Kroll, S.
    Jung, D.
    Tibes, R.
    Chiorean, E. G.
    Jones, S. F.
    Burris, H. A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 129 - 130
  • [32] COMPLETE PHASE IB STUDY OF TH-302 IN COMBINATION WITH GEMCITABINE (G), DOCETAXEL (D) OR PEMETREXED (P)
    Borad, M.
    Mita, A.
    Infante, J.
    Chiorean, E. G.
    Vlahovic, G.
    Armstrong, A.
    Traynor, A. M.
    Schelman, W.
    Langmuir, V.
    Eng, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 172 - 172
  • [33] Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma
    Ghobrial, Irene M.
    Laubach, Jacob
    Armand, Philippe
    Boswell, Erica
    Hanlon, Courtney
    Chuma, Stacey
    Chu, Esther Dawn
    Handisides, Damian
    Kroll, Stew
    Hickingbottom, Barbara
    Anderson, Kenneth Carl
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib.
    Starodub, Alexander
    Vaena, Daniel
    Pennington, Kenneth L.
    Kio, Ebenezer A.
    Bruetman, Daniel
    Thorne, Tracy
    Kroll, Stewart
    Milhem, Mohammed M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [35] Final results of a phase I study of TH-302, a hypoxia-activated cytotoxic prodrug (HAP)
    Bendell, J. C.
    Weiss, G. J.
    Infante, J. R.
    Chiorean, E. G.
    Borad, M.
    Tibes, R.
    Jones, S. F.
    Langmuir, V. K.
    Kroll, S.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Safety and activity of TH-302, a hypoxia-activated cytotoxic prodrug (HAP), in patients with metastatic melanoma and lung cancer
    Weber, R. W.
    Weiss, G. J.
    Chiorean, E. G.
    Senzer, N. N.
    Borad, M. J.
    Markovic, S.
    Molina, J. R.
    Langmuir, V. K.
    Lee, H.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.
    Starodub, Alexander
    Milhem, Mohammed M.
    Pennington, Kenneth Lee
    Kio, Ebenezer A.
    Bruetman, Daniel
    Thorne, Tracy
    Hickingbottom, Barbara
    Kroll, Stew
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
    Atkins, Michael B.
    Reiney, Ragini
    Sznol, Kudchadkar Mario
    McDermott, David F.
    Lotem, Michal
    Schachter, Jacob
    Wolchok, Jedd D.
    Urba, Walter John
    Kuzel, Timothy
    Schuchter, Lynn Mara
    Slingluff, Craig L.
    Ernstoff, Marc S.
    Fay, Joseph W.
    Friedlander, Philip Adam
    Gajewski, Thomas
    Zarour, Hassane M.
    Rotem-Yehudar, Rinat
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study
    Embaby, Alaa
    Kutzera, Joachim
    Geenen, Jill J.
    Pluim, Dick
    Hofland, Ingrid
    Sanders, Joyce
    Lopez-Yurda, Marta
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    Witteveen, Petronella O.
    Steeghs, Neeltje
    van Haaften, Gijs
    van Vugt, Marcel A. T. M.
    de Ridder, Jeroen
    Opdam, Frans L.
    GYNECOLOGIC ONCOLOGY, 2023, 174 : 239 - 246
  • [40] Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study
    Lee, Choong-kun
    Lee, Jii Bum
    Park, Se Jung
    Che, Jingmin
    Kwon, Woo Sun
    Kim, Hyo Song
    Jung, Minkyu
    Lee, Seulkee
    Park, Sook Ryun
    Koo, Dong-Hoe
    Lee, Hyun Woo
    Bae, Woo Kyun
    Jeung, Hei-Cheul
    Hwang, In Gyu
    Kim, Hyunki
    Nam, Chung Mo
    Chung, Hyun Cheol
    Rha, Sun Young
    GASTRIC CANCER, 2024, 27 (01) : 118 - 130
12345